Literature DB >> 34491822

Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.

Vishnu Prasad Pulappadi1, Shashi Paul1, Smriti Hari1, Ekta Dhamija1, Smita Manchanda1, Kamal Kataria2, Sandeep Mathur3, Kalaivani Mani4, Ajay Gogia5, Svs Deo6.   

Abstract

OBJECTIVE: To evaluate the role of axillary ultrasonography (axUS) and ultrasound-guided pre-operative wire localisation of pre-treatment positive clipped node (CN) for prediction of nodal response to neoadjuvant chemotherapy (NACT) in node positive breast carcinoma patients. METHODS AND MATERIALS: A prospective study was conducted between June 2018 and August 2020 after Ethics Committee approval. Breast carcinoma patients (cT1-cT4b) with palpable axillary nodes (cN1-cN3) and suitable for NACT were recruited after written informed consent. Single, most suspicious node was biopsied and clipped. Nodal response to NACT was assessed on axUS. Wire localisation of CN was performed prior to axillary lymph node dissection (ALND). Diagnostic performances of axUS and CN excision were assessed.
RESULTS: Of the 69 patients evaluated, 32 patients (mean age, 43.5 ± 11.8 years; females, 31/32 [97%]; pre-menopausal, 18/32 [56.3%]) with metastatic nodes who received NACT were included. Nodal pathological complete response rate was 34.4% (11/32) overall and 70% (7/10) in patients with ≤2 suspicious nodes on pre-NACT axUS. False-negative rates (FNRs) of axUS and CN excision were 4.8% and 28.6% respectively. Combination of post-NACT axUS and CN excision had an FNR of 4.8% overall and 0% in patients with ≤2 suspicious nodes on pre-NACT axUS.
CONCLUSION: Combination of AxUS and ultrasound-guided wire localisation of pre-treatment positive CN has high diagnostic accuracy for nodal restaging after NACT in node positive breast cancer patients. ADVANCES IN KNOWLEDGE: Addition of axUS assessment to wire localisation of CN reduces its FNR for detecting residual metastasis after NACT.

Entities:  

Mesh:

Year:  2021        PMID: 34491822      PMCID: PMC8553197          DOI: 10.1259/bjr.20210788

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  28 in total

Review 1.  Imaging axillary lymph nodes in patients with newly diagnosed breast cancer.

Authors:  Habib Rahbar; Savannah C Partridge; Sara H Javid; Constance D Lehman
Journal:  Curr Probl Diagn Radiol       Date:  2012 Sep-Oct

2.  The Relevance of Ultrasound Imaging of Suspicious Axillary Lymph Nodes and Fine-needle Aspiration Biopsy in the Post-ACOSOG Z11 Era in Early Breast Cancer.

Authors:  Gopal R Vijayaraghavan; Srinivasan Vedantham; Milliam Kataoka; Carolynn DeBenedectis; Robert M Quinlan
Journal:  Acad Radiol       Date:  2016-12-01       Impact factor: 3.173

3.  Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Huong T Le-Petross; Linda M McCall; Kelly K Hunt; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Karla V Ballman; Judy C Boughey
Journal:  AJR Am J Roentgenol       Date:  2018-01-30       Impact factor: 3.959

4.  Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Gary H Lyman; Mark R Somerfield; Linda D Bosserman; Cheryl L Perkins; Donald L Weaver; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2016-12-12       Impact factor: 44.544

5.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.

Authors:  Abigail S Caudle; Wei T Yang; Savitri Krishnamurthy; Elizabeth A Mittendorf; Dalliah M Black; Michael Z Gilcrease; Isabelle Bedrosian; Brian P Hobbs; Sarah M DeSnyder; Rosa F Hwang; Beatriz E Adrada; Simona F Shaitelman; Mariana Chavez-MacGregor; Benjamin D Smith; Rosalind P Candelaria; Gildy V Babiera; Basak E Dogan; Lumarie Santiago; Kelly K Hunt; Henry M Kuerer
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

6.  Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Tina J Hieken; Judy C Boughey; Katie N Jones; Sejal S Shah; Katrina N Glazebrook
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

7.  Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy.

Authors:  Steffi Hartmann; Toralf Reimer; Bernd Gerber; Johannes Stubert; Bernd Stengel; Angrit Stachs
Journal:  Eur J Surg Oncol       Date:  2018-06-09       Impact factor: 4.424

8.  Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.

Authors:  S You; D K Kang; Y S Jung; Y-S An; G S Jeon; T H Kim
Journal:  Br J Radiol       Date:  2015-08       Impact factor: 3.039

9.  Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study.

Authors:  Won Hwa Kim; Hye Jung Kim; See Hyung Kim; Jin Hyang Jung; Ho Yong Park; Jeeyeon Lee; Wan Wook Kim; Ji Young Park; Yee Soo Chae; Soo Jung Lee
Journal:  BMC Cancer       Date:  2019-08-30       Impact factor: 4.430

10.  Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?

Authors:  Jordan J Atkins; Catherine M Appleton; Carla S Fisher; Feng Gao; Julie A Margenthaler
Journal:  J Oncol       Date:  2013-02-11       Impact factor: 4.375

View more
  1 in total

1.  Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy.

Authors:  Minyan Chen; Shengmei Li; Meng Huang; Jingjing Guo; Xuan Huang; Wenhui Guo; Lili Chen; Yuxiang Lin; Lisa Jacobs; Chuan Wang; Fangmeng Fu
Journal:  Breast Cancer Res Treat       Date:  2022-09-13       Impact factor: 4.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.